Resectable Lung Cancer

Pembrolizumab as neoadjuvant and adjuvant therapy significantly extended OS among adults with resectable stage II, IIIA or IIIB non-small cell lung cancer, according to the agent’s manufacturer.

The addition of nivolumab to neoadjuvant chemotherapy followed by adjuvant nivolumab extended EFS among patients with resectable non-small cell lung cancer, according to the agent’s manufacturer.

In this video, Sonam Puri, MD, discusses the surgical outcomes from the phase 3 CheckMate 816 trial presented at this year’s virtual annual ASCO meeting.